1. Development of new biotechnological products such as polypeptide, protein and nucleic acid which target serious diseases in nervous system, tumor, cardiovascular system, AIDS and immunodeficiency, etc.;
2. Selection of one batch of biotechnological products and vaccines as well as diagnostic monoclonal antibody that possess good market prospects, with the development focused on hepatitis B gene vaccine and monoclonal antibody diagnostic reagent, etc.;
3. The development of targeted drug is mainly dedicated to antitumor drugs. There is indeed one so-called "fail to tell friend from foe" problem for antitumor drugs, which also kill normal cells when killing cancel cells. For this problem, the targeting therapy is proposed, which means searching for targets by means of antibody and correctly introducing drug into the lesion without injuring other tissues and cells, just like the navigator of a missile;
4. R&D of humanized monoclonal antibody. Antibody can fight against various pathogens and can be the guide device, however, most of current monoclonal antibodies are murine antibody and viewed as antigen by heterogeneous organisms, and will induce antibody (antiantibody) or stimulate immune response when injected to human body.
5. R&D of blood substitutes is still important. The use of genetic engineering to develop blood substitutes attracts people's attention because human blood is inevitably contaminated by various pathogens, such as HIV and HBV, and there are commonly the cases where persons accepting blood transfusion are infected with HIV or HBV via blood transfusion.
